DOSAGE INDEX / SINGLE
Glutathione
Research, reported schedules and supply planning.
Examine mixed oral Glutathione findings, biomarker limits, skin research and FDA alerts about endotoxin risks in compounded injectable products.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–200 mg per administration
- Frequency
- Daily or alternate days; other maintenance examples differ
- Cycle / observation period
- 4–8 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 600 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A six-month randomized trial reported on 54 nonsmoking adults and measured GSH across several compartments. The investigators found increases in body stores with oral supplementation; many changes depended on dose and time, and levels generally returned toward baseline after a one-month washout. Some immune-related measurements were assessed in a subset. [1]
- A 2025 randomized trial involved 40 people with mild-to-moderate acne. After four weeks, the oral Glutathione group showed nonsignificant reductions in the studied nitric-oxide and interleukin-1 alpha measurements. Seven participants in that group improved from moderate to mild clinical severity, but the authors described the overall findings as a nonsignificant trend requiring further study. [2]
- On August 27, 2026, FDA reported adverse events in at least 30 patients after intravenous Glutathione alone or with other ingredients. The products involved dietary-supplement-grade material from a specified lot. Reported events included fever, chills, pain, dizziness and shock or sepsis-like symptoms, with some hospitalizations. FDA described the pattern as consistent with excessive endotoxin exposure and noted related recalls. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 20 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original longer-duration trial
- Original acne study
- FDA alert
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- NatureFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.